

## Severe Bronchopulmonary Dysplasia Ventilator Strategies and Concepts of Care

David N. Matlock, Jr., MD  
DMatlock@uams.edu

1

## Objectives

- Define and describe BPD
- Discuss concepts of care in BPD
- Evaluate data from PASSIVE study

2


## Abbreviations

- BPD, Bronchopulmonary Dysplasia
- RDS, Respiratory Distress Syndrome
- PEEP, Positive End Expiratory Pressure
- PPV, Positive Pressure Ventilation
- NICU, Neonatal Intensive Care Unit
- PICU, Pediatric Intensive Care Unit
- GA, Gestational Age at birth
- PMA, Postmenstrual Age
- wk, weeks
- SGA, Small for Gestational Age
- IQR, Interquartile Range
- SIMV, Synchronized Intermittent Mandatory Ventilation
- AC, Assist Control
- VT/VC, Volume-Targeted/Volume-Control
- PC, Pressure Control
- NAVA, Neurally Adjusted Ventilatory Assist
- CPAP, Continuous Positive Airways Pressure
- PIP, Peak Inspiratory Pressure
- MAP, Mean Airway Pressure
- Ti, inspiratory Time
- HFNC, High Flow Nasal Cannula
- LFNC, Low Flow Nasal Cannula
- NIV, Noninvasive Ventilation
- NIPPV, Noninvasive intermittent positive pressure ventilation
- Vt, tidal volume
- RR, respiratory rate

3

## BPD: History

- 1967 Northway described a **heterogenous lung disease with fibrosis and cor pulmonale** in surviving infants born prematurely and treated with high airway pressures and FiO<sub>2</sub>.




- The **spectrum** of BPD has **broadened**, and the **incidence** of BPD has **increased**.

4

## BPD: Features

- **Radiographic features** –Heterogenous hyperinflation, atelectasis, densities extending to periphery
- **Pathologic features** –Alternating **emphysematous/cystic** and **collapsed** areas, interstitial fibrosis and edema, dilated tortuous **lymphatics**, **vascular** medial muscle hypertrophy
  - **Decreased surface area** for gas exchange –Marked decrease in number of alveoli and capillaries

5



6

## BPD Classifications

- Improved survival, changes in clinical practice (low flow high FiO<sub>2</sub>, HFNC, NIPPV), and knowledge of outcomes necessitate a new classification with prognostic implications.
- Simple new classification system linked to 2-year outcomes data.



7

## BPD Classifications

- 1978 NHLBI criteria, published by Tooley and Bancalari 1979
  - Oxygen use at 28 days of life
- 1988 Shennan tailored diagnosis to predict outcomes at 2 years
  - Oxygen use at 36wks PMA
- 2001 NHLBI Severity-based categories
  - Mild (RA), moderate (<30% O<sub>2</sub>), or severe (>30% O<sub>2</sub> or CPAP/PPV) at 36wk PMA or discharge
- 2018 NICHD Workshop
  - Grades 0-3 based on FiO<sub>2</sub> and type of support at 36wk PMA or discharge
  - Reflects current respiratory management, but not outcomes-based.
- 2019 Jensen Definition
  - Outcomes-based. Simple. N = 2677.



8

### Are these cases equally "severe"?

GA = 28 weeks PMA = 36 weeks



Nasal Cannula  
1L/min  
35% FiO<sub>2</sub>



Nasal CPAP  
6cm H<sub>2</sub>O  
35% FiO<sub>2</sub>



Invasive Ventilation  
Vt 7mL/kg / PEEP 6  
35% FiO<sub>2</sub>

\*Slide from presentation by Erik Jensen CHOP CLD Conference 3-13-2019

9

## 2018 NICHD Workshop BPD Classification

Table 1. Suggested refinements to the definition of BPD

A premature infant (<32 weeks' gestational age) with BPD has persistent parenchymal lung disease, radiographic confirmation of parenchymal lung disease, and at 36 weeks PMA requires 1 of the following FiO<sub>2</sub> ranges/oxygen levels/O<sub>2</sub> concentrations for ≥3 consecutive days to maintain arterial oxygen saturation in the 90%-95% range.

Grades	Invasive IPPV*	n-CPAP, NIPPV, or nasal cannula ≥ 3 L/min	Nasal cannula flow of 1-3 L/min	Hood O <sub>2</sub>	Nasal cannula flow of <1 L/min
I	—	21	22-29	≥30	22-70
II	21	22-29	≥30	≥30	>70
III	≥21	≥30			

III(A) Early death (between 14 days of postnatal age and 36 weeks) owing to persistent parenchymal lung disease and respiratory failure that cannot be attributable to other neonatal morbidities (eg, necrotizing enterocolitis, intraventricular hemorrhage, redirection of care, episodes of sepsis, etc).

\*Excluding infants ventilated for primary airway disease or central respiratory control conditions. Values are percent.  
CPAP: continuous positive airway pressure; IPPV, intermittent positive pressure ventilation; n-CPAP, nasal continuous positive airway pressure; NIPPV, noninvasive positive pressure ventilation.



10

## Variability Among "NIH Severe BPD"

- High variability within category of "NIH Severe BPD"
- Additional phenotyping and Jensen definitions are helpful
- Descriptive data will facilitate further study



11


## Optimal BPD Definition

Room Air No 28 day O <sub>2</sub> assessment	Treatment with the following respiratory support at 36 weeks PMA or discharge home if earlier:			
	NC ≤ 2L/min "low" flow	NC > 2L/min "high" flow	nCPAP NIPPV	Invasive PPV
	FiO <sub>2</sub> <30% FiO <sub>2</sub> ≥30%	FiO <sub>2</sub> <30% FiO <sub>2</sub> ≥30%	Any FiO <sub>2</sub>	FiO <sub>2</sub> <30% FiO <sub>2</sub> ≥30%
No BPD	Grade 1	Grade 2	Grade 3	

- Best predictor of both composite study outcomes
- No need to assess for 28 days of oxygen therapy
- Severity graded based on the **mode of support at 36 weeks PMA**, irrespective of oxygen level

\*Slide from presentation by Erik Jensen CHOP CLD Conference 3-13-2019

12




13

## Management Strategies in Severe Bronchopulmonary Dysplasia

- No large-scale studies
- Heterogenous disease
- Need to shift from **acute care strategies** designed to minimize exposure to positive pressure to **long-term strategies** designed to promote growth and development



14




15

## BPD Management: Overview

- Support growth and development while minimizing further lung damage
- Need to consistently apply what we know while developing and investigating optimal strategies



16



17

## Open Lung Strategy

- Optimize distribution of ventilation
- Identify appropriate tidal volume and PEEP
- Minimize atelectasis and V/Q mismatch
- Minimize oxygen toxicity



18

## “Whole Baby” Approach

- Gas exchange may be acceptable despite poor lung parenchymal and vascular growth, abnormal pulmonary and airways smooth muscle remodeling, and stalled injury repair
- Inadequate data to suggest optimal PaCO<sub>2</sub> and SpO<sub>2</sub>



19

Phase I (Unstable)	Phase II (Transitional)	Phase III (Pro-growth)	Phase IV (Convalence)
Ventilator mgms based on most likely physiology	Adjust vent support for increased activity	Wean vent support while maintaining activity	Transition to home or referring center
<b>Characteristics:</b> High O <sub>2</sub> requirement Frequent desaturations Air-trapping IV sedation/paralysis +/- high steroids > 1.5 mg/kg +/- Pulm Hypertension	<b>Characteristics:</b> Tolerating off paralysis Weaning enteral sedatives P-HTN stable, decreasing Steroids < 1mg/kg/day Emerging developmental state: tolerates cares	<b>Characteristics:</b> PS/CPAP trials or PP weans Maintains develop activities Tolerates postural activity Good linear growth Low steroids < 0.2/kg Wt/Lg ratio improving	<b>Characteristics:</b> Minimal and FIO <sub>2</sub> < 0.4 PS/CPAP, w/ LTV Happy child, consistent interactions Weaning bronchodilators and diuretics
<b>Physiology:</b> unstable, long time const, ? obstructive • Hypoxemia, FIO <sub>2</sub> > 0.6 • V/Q mismatch • A/W obstruction • P-HTN often active	<b>Physiology:</b> still labile at times, fragile • Stable sats, FIO <sub>2</sub> ≤ 0.4 • P-HTN improving • A/W obstruction active • +/- airway concerns	<b>Physiology:</b> stable, with tolerance of cares, activities • FIO <sub>2</sub> < 40% and stable • P-HTN stable or resolved • A/W obstruction resolving • Airway secure	<b>Physiology:</b> stable at all times except for illness • FIO <sub>2</sub> 0.3 or less • A/W obstruction w/o • Stable w/ postural cares • Good linear growth
<b>Transition to Phase II:</b> • Oxygenation improve • Work of breathing still concerning at times • Wean steroids < 1/kg • Central lines out • Pulm HTN improved	<b>Transition to Phase III:</b> • Off IV sedation • Oxygenation improves • Work of breathing better • Steroids ≤ 0.2mg/kg • Growth velocity still poor	<b>Transition to Phase IV:</b> • Stable oxygenation • Secure airway • Comfortable breathing • Developmental progress • Progress on less sedative • Good growth velocity	<b>Transition toward D/C:</b> • Off sedatives • Off steroids (or on hydrocortisone base) • Excellent growth • Parental teaching • Disposition pending

20

## Blood Gases

- Physical examination is at least as informative to guide weaning/escalation of support
- Avoid using permissive hypercarbia merely to avoid endotracheal intubation in infant with increased work of breathing and extrauterine growth failure



21

## Physical Examination

- Assessing work of breathing while sleeping may underestimate the degree of respiratory distress encountered during activity.
- Tolerance of therapies (or the Behavioral Sign of Respiratory Instability Scale) is an important indicator of adequacy of support.



22

## Noninvasive Respiratory Support

- Goal is to encourage growth and development.
- Goal is not primarily to avoid invasive ventilation
- Monitor for poor growth, worsening pulmonary hypertension, inability to tolerate activities, and repeated hypoxemic spells



23

## Weaning Strategies

- **RDS**
  - Rapid weaning corresponding to rapid improvement
- **BPD**
  - Slow weaning corresponding to gradual improvement
  - Avoid daily changes
  - Signs of inadequate support may be subtle, gradually develop, easily overlooked



24

## BPD Spells

- Acute, severe hypoxemia with airway collapse and/or pulmonary hypertensive crisis often associated with agitation or stooling
- Brief periods of higher PEEP may help
- Developing an individualized bedside plan is helpful




25

## Ventilation Strategies in Severe Bronchopulmonary Dysplasia

- No large-scale studies
- Heterogenous disease
- Different lung mechanics from RDS
- Need to shift from **acute care strategies** designed to minimize exposure to positive pressure to **long-term strategies** designed to promote growth and development



26



27

### RDS

- Low compliance, near-normal resistance
- Homogenous disease
- Goal is to minimize exposure to mechanical ventilation
- Frequent blood gases and adjustments

### BPD

- Low compliance, high resistance
- Heterogenous disease
- Goal is to support growth and development, promote healing
- Less frequent gases and adjustments



28


Parameter	Healthy	RDS	BPD
<b>Compliance</b> (mL/cm H <sub>2</sub> O)	3-5	0.5-1	<1
<b>Resistance</b> (cm H <sub>2</sub> O/L/s)	20-40	>40	>150
<b>Time Constant</b> (s)	0.09-0.15	0.05	>0.15




29

## Time Constant (TC) = Resistance x Compliance

- How quickly lung volumes change
- In 1 TC, alveoli empty 63%.
- 2 TC, 84%. 3 TC, 95%.
- 3-5 TCs required for adequate inspiration or expiration.
- \*0.09 – 0.15s in healthy newborns, 0.05s in RDS, >0.15s in CLD.




Time Constants



30

## Airways Resistance



31

## The Ventilator is our Friend

- Holistic care, where management of lung disease and changes to level of support include consideration of strategies to improve somatic growth and neurodevelopment
- Optimize gas exchange, minimize dead space, limit excessive work of breathing, avoid intermittent hypoxemia




32

## BPD Phenotypes

1. Lung **parenchymal**
  2. Pulmonary **vascular**
  3. Small/large **airway** dysfunction
- Often a **mixed** phenotype with components of all three.



33



34

## Ventilator Strategies by Phenotype

- **Airways malacia**
  - Prevent airway collapse with optimal PEEP
- **Parenchymal disease**
  - Prevent atelectasis with adequate tidal volume, inspiratory time, and PEEP
- **Pulmonary vascular disease**
  - Decrease pulmonary vascular resistance



35


## Intrinsic PEEP (“Auto-PEEP” or PEEPi)

- Expiration prolonged by high airways resistance then interrupted by the subsequent inspiration
- High end-expiratory lung volumes cause hyperinflation
- Infant must overcome PEEPi to pneumatically trigger a spontaneous breath



36

## WASTED EFFORTS




\*Slide from presentation by  
Natalie Napolitano at  
CHUP CLD Conference 3-  
15-2019



37

## Two Compartment Model for Ventilation in Severe BPD

Illustration of **A**, 2-zone disease vs **B**, multizone (heterogeneous) disease. **A**, Chest CT in a patient with acute respiratory distress syndrome. **B**, Chest CT in a patient with type 2 sBPD and diffuse, heterogeneous disease. **C**, Schematic illustrating concept of multizone disease. Time constant, T = resistance x compliance.



38

## Multicenter Point Prevalence Study

McKinney RL, Napolitano N, Levin JJ, Kiehl M, Abman SH, Guaman MC, Rose RB, Courtney SE, Matlock D, Agarwal A, Leeman RT, Sanlorenzo LA, Sindelar R, Coliaco JM, Baker CD, Hannan KE, Douglass M, Kildredge LC, Lai Y, McGrath-Morrow SA, Tracy MC, Truong M, Lewis T, Musillo AL, Vaszler M, on behalf of the BPD Collaborative. Ventilatory Strategies in Infants With Established Severe Bronchopulmonary Dysplasia: A Multicenter Point Prevalence Study. *The Journal of Pediatrics* (2021), doi: <https://doi.org/10.1016/j.jpeds.2021.10.036>.

- Point prevalence study to describe respiratory management practices of infants with severe BPD
- Ventilator support:
  - Type
  - Settings
- 187 infants, 15 centers, US and Sweden, 51% invasively ventilated



39

## Methods

- 8 AM October 29<sup>th</sup>, 2019
- Eligibility Criteria:
  - <24 months chronologic age
  - **Never discharged**
  - Severe BPD (2001 NIH): <32 weeks GA, >28 days of support required,  $\geq 0.30$  FiO<sub>2</sub> or PPV at 36 weeks
- Exclusion Criteria:
  - Requiring support due to surgical, neurologic, or anatomic reasons



40

## Results

- 16 hospitals (15 institutions) in US and Sweden
- 192 eligible infants (complete data from 187)
- Median PMA 46 weeks
- **86% in NICU**, 6% in PICU, 6% “Stepdown,” 2% General Ward



41

## Results

- 27% s/p tracheostomy (53% of invasive group)
  - Median PMA 52wks
- **60% male**
- Median GA 25 weeks
- Median birth weight 710 grams



42



## BPD Classification

- Severe BPD **Type I**: Requiring noninvasive support at 36 wks PMA
- Severe BPD **Type II**: Requiring invasive support at 36 wks PMA



43

## BPD Classification

- **Type II** infants (Invasively Ventilated at 36wk):
  - **Lower birthweight** (631g vs 780g,  $p=0.003$ )
  - **Higher FiO<sub>2</sub>** requirements at 36 and 40 weeks PMA
  - No difference in other demographics



44

## Support at 36 weeks PMA

- 91 of 176 were on noninvasive support at 36 weeks, **23 of these 91 were on invasive support at the time of the study.**
- 74% of those invasively ventilated at 36 weeks remains on ventilator on the study day (median PMA 46 weeks).




45

## Invasive Support on Study Day

- Invasive ventilation:
  - SIMV (64%), AC (21%)
  - VT/VC (50%), PC (43%)
- Noninvasive ventilation:
  - Nine modes, varied significantly by center



46



47


## Median (IQR) Invasive Ventilator Settings

- PIP: 32 (25.5-50.5)
- PEEP: 10 (8-11)
- FiO<sub>2</sub>: 0.33 (0.29-0.4)
- MAP: 17 (13.8-20)




48





49



50

**Table III**  
Comparison of ventilator strategies and goals during progression of early disease to established sBPD (modified from Abman and Neil<sup>29</sup>)

Early (prevention)	Strategies to prevent acute lung injury	Low tidal volumes (3-5 mL/kg) Short inspiratory times (0.2-0.3 seconds) Increased PEEP for lung recruitment without overdistension Adjust FIO <sub>2</sub> to target SpO <sub>2</sub> (range: 91%-95%) Permissive hypercapnia
Late (established BPD)	Strategies for gas exchange	Marked regional heterogeneity Larger tidal volumes (10-12 mL/kg) Longer inspiratory times (>0.6 s) Airway obstruction
	Strategies for gas exchange	Slower rates allow for better emptying, especially with larger tidal volumes (10-20 bpm) Complex roles for PEEP with dynamic airway collapse Interactive effects of ventilator strategies Changes in flow, tidal volume, inspiratory and expiratory times, and pressure support are highly interdependent Overdistension can increase agitation and paradoxically worsen ventilation Adjust FIO <sub>2</sub> to target higher SpO <sub>2</sub> (92%-95%) Permissive hypercapnia to facilitate weaning


51

## Noninvasive Ventilator Settings

- 5 Modes: HFNC (41%), LFNC (28%), CPAP (26%), NIV NAVA (3%), NIPPV (2%)
- HFNC used most commonly
- Very few babies on NIPPV or NIV NAVA



52



53

## High Variability in Modes and Settings

- Partially attributable to lack of prospective randomized controlled trials comparing:
  - Mode of support
  - Optimal PEEP
  - Synchronization



54

## Conclusions

- A team-based, holistic approach will give a babies with BPD the best outcomes.
- Collaboration among centers will help us improve our care of patients with BPD.



55

## References

- Abman SH, Collico JM, Shepherd EG, Kesler M, Cuevas-Guaman M, Welty SE, Truong WE, McGrath-Morrow SA, Moore PE, Rhein LM, Kirpalani H, Zhang H, Gratny L, Lynch SK, Curtiss J, Stonestreet BS, McKinney RL, Dysart KC, Gien J, Baker CD, Donohue PK, Austin E, Filke C, Nelin LD; Bronchopulmonary Dysplasia Collaborative. Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia. *J Pediatr*. 2017 Feb;181:12-28.e1. doi: 10.1016/j.jpeds.2016.10.082. Epub 2016 Nov 28. PMID: 27908648; PMCID: PMC5562402.
- McKinney RL, Napolitano N, Levin JJ, Kiehl M, Abman SH, Guaman MC, Rose RS, Courtney SE, Matlock D, Agarwal A, Leeman KT, Sanlorenzo LA, Sindelar R, Collico JM, Baker CD, Haman KE, Douglass M, Eldredge LC, Lai K, McGrath-Morrow SA, Tracy MC, Truong W, Lewis T, Murrillo AL, Kesler M, on behalf of the BPD Collaborative. Ventilatory Strategies in Infants With Established Severe Bronchopulmonary Dysplasia: A Multicenter Point Prevalence Study. *The Journal of Pediatrics* (2021), doi: <https://doi.org/10.1016/j.jpeds.2021.10.036>.
- Gibbs K, Jensen EA, Alexiou S, Munson D, Zhang H. Ventilation Strategies in Severe Bronchopulmonary Dysplasia. *Neoreviews*. 2020 Apr;21(4):e226-e237. doi: 10.1542/neo.21-4-e226. PMID: 32238485.
- Bapat, R., Nelin, L., Shepherd, E. et al. A multidisciplinary quality improvement effort to reduce bronchopulmonary dysplasia incidence. *J Perinatol* 40, 681–687 (2020). <https://doi.org/10.1038/s41372-019-0574-8>
- Jensen EA, Wright CJ. Bronchopulmonary Dysplasia: The Ongoing Search for One Definition to Rule Them All. *J Pediatr* 2018, 197: 8-10.



56

## Thank You!

- <https://base.uams.edu/redcap/surveys/?s=TTE7FXCRPW>
- David N. Matlock, Jr., MD
- Dmatlock@uams.edu



57